Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australian bourse filing.
Four out of seven patients in the group have achieved a complete response following treatment with azer-cel, chemotherapy, as well as a low dose of interleukin 2, a protein that affects what happens between cells in the immune system, the filing added.
Azer-cel is a chimeric antigen receptor T-cell therapy, which targets CD19 to treat blood cancers.
Imugene said that it remains focused on continuing enrollment in the group, as well as evaluating the long-term durability of responses.
The firm's shares rose 8% in recent trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.